Jayden Martinez

Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.

Cooley advised TriSalus Life Sciences, an oncology company with a focus on treatments for patients with liver and pancreatic tumors, on its merger with MedTech Acquisition Corporation.

Cooley advised Ionis Pharmaceuticals, a biotechnology company, in its $575 million aggregate principal amount of convertible senior notes.

Cooley represented Shoreline Biosciences, a biotechnology company developing cellular immunotherapies, on its $140 million financing led by Ally Bridge Group. Partner Tom Coll led the Cooley team.

Cooley advised Longboard Pharmaceuticals on its $80 million initial public offering of 5,000,000 shares of common stock. Longboard Pharmaceuticals, whose securities now trade on the Nasdaq Global Market under the symbol LBPH, is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Partners Steven Przesmicki and Charlie Kim led the Cooley team.